Home   Case of Week Home   Jobs  Conferences   Fellowships   Books

29 July 2011 – Case of the Week #211

This email is only sent to subscribers. To subscribe or unsubscribe to this or our other email lists, click here.

All cases are archived on our website. To view them sorted by number, diagnosis or category, visit our Home Page and click on the Case of the Week button on the left hand side.

Thanks to Ashish Bansal, Betsi Cadwaladr University Health Board (North Wales, U.K.), for contributing this case. To contribute a Case of the Week, follow the guidelines on our Case of the Week page.


CancerTYPE ID is a standardized, objective molecular test based on the differential expression of 92 genes, that classifies tumors by matching the gene expression pattern of a patient’s tumor tissue to a database of known tumor types and histological subtypes.

CancerTYPE ID’s database includes 2,206 tumors from multiple tumor banks, selected to provide broader and deeper representation of the heterogeneity of tumors. The 92-gene assay does not overlap with IHC markers, providing complementary data to standard tumor diagnosis.

CancerTYPE ID uses real-time reverse transcription polymerase chain reaction (RT-PCR). A very low copy number of RNA molecules can be detected, thus reducing the sample tissue required for testing. Testing is conducted and results are generated at bioTheranostics' CAP-accredited, CLIA-certified laboratory.

For more information, click here.

Advertisement

Website news:

(1) Our Buyer's Guide - Feature Page for July highlights Imaging / digital / photography, and includes Celestron, Leica, Milestone Medical, Olive Tree Media LLC, Optronics, Photodyne and SPOT Imaging Solutions.

(2) We are looking for reviewers for part/all of these chapters: Coagulation, Salivary Glands, Stains, Uterus; also Fallopian Tubes, Lung-tumor, Ureters, Urethra, Vagina, Vulva. If interested, contact Liz at eapathology@gmail.com, and send a copy to NatPernick@hotmail.com.

(3) We have now updated the Bladder chapter.

Case of the Week #211

Clinical History:

A 57 year old woman presented with post-menopausal bleeding. An endometrial polyp was removed piecemeal at hysteroscopy, the largest fragment was 18 mm.

Micro images:

       

   
Inhibin (left) and Melan-A (right)

       
ER (left), PR (middle), CD10 (right)


What is your diagnosis?































Diagnosis:

Uterine tumour resembling ovarian sex cord tumors (UTROSCT)

Discussion:

Tumors of the uterus resembling ovarian sex cord tumors were first described by Clement and Scully (Am J Clin Pathol 1976;66:512). They are divided into 2 groups: group 1 - endometrial stromal tumors with sex cord-like elements (ESTSCLE), and group 2 - mural uterine tumors. In group 1 tumors, the sex cord component constitutes a minor portion of an endometrial stromal neoplasm. In group 2 tumors, it is the predominant or exclusive component of a uterine wall lesion composed of various mesenchymal elements.

UTROSCT are polypoid or nodular neoplasms, which generally arise in the fourth to sixth decade of life. Grossly, they are polypoid or nodular, typically in the myometrium. Histologically, they are well circumscribed, polyphenotypic neoplasms, with a predominant, if not exclusive, pattern of cords, nests and trabeculae containing epitheloid cells resembling granulosa or Sertoli cell tumors of the ovary. True Leydig cell differentiation is rare (Mod Pathol 2006;19:17).

These tumors typically express at least two “sex cord markers” of calretinin, inhibin, CD99 and Melan A (Int J Gynecol Pathol 2008;27:229), although a recent study substituting WT1 for CD99 found less frequent immunoreactivity (Am J Surg Pathol 2010;34:1749). They also express myoid markers, epithelial markers and hormone receptors.

The origin of these tumors is uncertain. They may derive from an uncommitted cell with the capacity to differentiate along several lines (J Clin Pathol 2007;60:1148). Although these tumors often express smooth muscle markers, there are no ultrastructural features of smooth muscle differentiation (Ultrastruct Pathol 2010;34:16). Although they resemble ESTSCLE, they lack the JAZF1-JJAZ1 translocation frequently associated with endometrial stromal tumors (Am J Surg Pathol 2009;33:1206).

The differential diagnosis includes metastatic ovarian sex cord tumors (different clinical history) and mixed mullerian tumors (histologic evidence of malignancy). If one inappropriately focuses on immunohistochemistry results, an erroneous diagnosis of a myoid tumor (such as vascular plexiform leiomyoma, Ann Diagn Pathol 2010;14:355) or an epithelial tumor may occur.

Excision by hysterectomy is usually curative, although some recommend fertility-sparing surgery in select patients, with careful follow up. Tumors of the uterus resembling ovarian sex cord tumors typically have benign behavior, although metastases have rarely been reported (Gynecol Oncol 2009;114:140, Int J Gynecol Pathol 2008;27:58).


Nat Pernick, M.D., President
and Liz Parker, B.A., Associate Medical Editor
PathologyOutlines.com, Inc.
30100 Telegraph Road, Suite 408
Bingham Farms, Michigan (USA) 48025
Telephone: 248/646-0325
Email: NatPernick@Hotmail.com
Alternate email: NatPernick@gmail.com